A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

This phase II study is testing a combination treatment — dexamethasone (a steroid), azacitidine, pegaspargase, and tislelizumab (an immunotherapy drug) plus radiation therapy — for people with early-stage extranodal NK/T-cell lymphoma, a rare type of blood cancer that often affects the nose and throat. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of extranodal NK/T-cell lymphoma - Your cancer is at stage I or II (early stage, not yet widely spread) - You have at least one tumor that can be measured on a scan - Your blood counts and general health meet the study requirements **You may NOT be eligible if...** - Your diagnosis has not been confirmed by a tissue sample (biopsy) - You are pregnant or breastfeeding, or not willing to use contraception - You have significant heart problems (abnormal heart rhythms, recent heart attack, or heart failure) - You have active bleeding, a blood clot, recent stroke, or active infection - You have a serious psychiatric condition Talk to your doctor to see if this trial is right for you.